[1]袁 瑞,余亚莉.吡格列酮二甲双胍片治疗胰岛素抵抗型多囊卵巢综合征患者的疗效[J].医学信息,2021,34(01):158-160.[doi:10.3969/j.issn.1006-1959.2021.01.043]
　YUAN Rui,YU Ya-li.Efficacy of Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets in the Treatment of Patients with Insulin-resistant Polycystic Ovary Syndrome[J].Medical Information,2021,34(01):158-160.[doi:10.3969/j.issn.1006-1959.2021.01.043]
点击复制

吡格列酮二甲双胍片治疗胰岛素抵抗型多囊卵巢综合征患者的疗效()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年01期
页码:
158-160
栏目:
药物与临床
出版日期:
2021-01-01

文章信息/Info

Title:
Efficacy of Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets in the Treatment of Patients with Insulin-resistant Polycystic Ovary Syndrome
文章编号:
1006-1959（2021）01-0158-03
作者:
袁 瑞; 余亚莉
（1.西安医学院，陕西 西安 710021； 2.西北妇女儿童医院妇四科，陕西 西安 710054)
Author(s):
YUAN Rui; YU Ya-li
(1.Xi’an Medical University,Xi’an 710021,Shaanxi,China; 2.Subject Four,Department of Gynecology,Northwest Women and Children’s Hospital,Xi’an 710054,Shaanxi,China)
关键词:
多囊卵巢综合征; 胰岛素抵抗; 吡格列酮二甲双胍片
Keywords:
Polycystic ovary syndrome; Insulin resistance; Pioglitazone Hydrochloride and Metformin Hydrochloride tablets
分类号:
R711.75
DOI:
10.3969/j.issn.1006-1959.2021.01.043
文献标志码:
A
摘要:
目的 探究吡格列酮二甲双胍片治疗胰岛素抵抗（IR）型多囊卵巢综合征（PCOS）患者的临床疗效。方法 选取2018年6月~2019年12月在西北妇女儿童医院收治的50例IR型PCOS患者作为研究对象，予以同等剂量的吡格列酮二甲双胍片治疗12周后，比较治疗前后性激素水平、血糖、血脂、胰岛素抵抗指数、体重指数、甲状腺功能及肝肾功能指标变化情况。结果 治疗后患者LH、PRL、T低于治疗前，差异有统计学意义（P＜0.05）；而治疗前后患者FSH、E2、P比较，差异无统计学意义（P＞0.05）。治疗后患者FPG、FINS、PBG、PINS、TC、LDL-C及HOMA-IR低于治疗前，HDL-C高于治疗前，差异有统计学意义（P＜0.05）；而治疗前后患者TG比较，差异无统计学意义（P＞0.05）。治疗后患者TSH、ALT、AST、SCr、BUN及BMI低于治疗前，差异有统计学意义（P＜0.05）。结论 吡格列酮二甲双胍片能改善IR型PCOS患者的胰岛素抵抗，增加胰岛素的敏感性，调节患者体内性激素水平，纠正糖脂代谢紊乱，同时也能改善患者的甲状腺功能，并且对患者的肝肾功能无明显影响。
Abstract:
Objective To explore the clinical efficacy of Pioglitazone Hydrochloride and Metformin Hydrochloride tablets in the treatment of patients with insulin resistance(IR) type polycystic ovary syndrome(PCOS) and basis for the treatment of IR type PCOS patients.Methods 50 patients with IR type PCOS treated in gynecological endocrine clinic from June 2018 to December 2019 in Northwest Women and Children’s Hospital are selected as the research subjects. After 12 weeks of treatment with the same dose of Pioglitazone Hydrochloride and Metformin Hydrochloride tablets, we observe the changes of sex hormone level, blood glucose, blood lipid, insulin resistance index, body mass index, thyroid function and liver and kidney function index before and after treatment.Results After treatment, the LH, PRL, and T of the patients were lower than before treatment, the difference was statistically significant (P<0.05); while the comparison of FSH, E2, P before and after treatment, the difference was not statistically significant (P>0.05). After treatment, the FPG, FINS, PBG, PINS, TC, LDL-C and HOMA-IR of the patients were lower than before treatment, and HDL-C was higher than before treatment, the difference was statistically significant (P＜0.05); and the comparison of TG before and after treatment,the difference was not statistically significant (P>0.05). The TSH, ALT, AST, SCr, BUN and BMI of the patients after treatment were lower than those before treatment,the difference was statistically significant (P<0.05).Conclusion Pioglitazone Hydrochloride and Metformin Hydrochloride tablets can improve insulin resistance, increase insulin sensitivity, regulate the level of sex hormones in patients，correct the disorder of glycolipid metabolism with IR type PCOS, but also improve the thyroid function of patients, and have no obvious effect on the liver and kidney function of patients.

参考文献/References:

[1]Khan MJ,Ullah A,Basit S.Genetic Basis of Polycystic Ovary Syndrome(PCOS):Current Perspectives[J].Appl Clin Genet,2019(12):249-260. [2]Meier RK.Polycystic Ovary Syndrome[J].Nurs Clin North Am,2018,53(3):407-420. [3]Burghen GA,Givens JR,Kitabchi AE.Correlation of hyperandrogenism with hyperixsulinism in polycystic ovarian disease[J].J Clin Endocrinol Metab,1980,50(1):113-116. [4]中华医学会妇产科学分会内分泌学组及指南专家组.多囊卵巢综合征中国诊疗指南[J].中华妇产科杂志,2018(1):2-6. [5]Escobar-Morreale HF.Polycystic ovary syndrome:definition, aetiology,diagnosis and treatment[J].Nat Rev Endocrinol,2018,14(5):270-284. [6]Bednarska S,Siejka A.The pathogenesis and treatment of polycystic ovary syndrome:what’s new[J].Adv Clin Exp Med,2017,26(2):359-367. [7]Rocha AL,Oliveira FR,Azevedo RC,et al.Recent advances in the understanding and management of polycystic ovary syndrome[J].F1000 Res,2019(8):F1000 Faculty Rev-565. [8]Barber TM,Hanson P,Weickert MO,et al.Obesity and Polycystic Ovary Syndrome:Implications for Pathogenesis and Novel Management Strategies[J].Clin Med Insights Reprod Health,2019(13):1179558119874042. [9]El-khayat W,Moety Abdel G,Al Mohammady M,et al.A randomized controlled trial of clomifene citrate,metformin,and pioglitazone versus letrozole,metformin,and pioglitazone for clomifene-citrate-resistant polycystic ovary syndrome[J].Int J Gynaecol Obstet,2016(132):206-209. [10]Wu Y,Li P,Zhang D,et al.Metformin and pioglitazone combination therapy ameliorate polycystic ovary syndrome through AMPK/PI3K/JNK pathway[J].Exp Ther Med,2018,15(2):2120-2127. [11]Sohrevardi SM,Nosouhi F,Hossein Khalilzade S,et al.Evaluating the effect of insulin sensitizers metformin and pioglitazone alone and in combination on women with polycystic ovary syndrome:An RCT[J].Int J Reprod Biomed(Yazd),2016,14(12):743-754.

相似文献/References:

[1]吕 宁,徐 昕,黄 永,等.公安民警皮肤软纤维瘤与代谢综合征危险因素相关性研究[J].医学信息,2018,31(10):69.[doi:10.3969/j.issn.1006-1959.2018.10.021]
　LV Ning,XU Xin,HUANG Yong,et al.Correlative Study on Skin Soft Fibroma and Risk Factors of Metabolic Syndrome in Public Security Police[J].Medical Information,2018,31(01):69.[doi:10.3969/j.issn.1006-1959.2018.10.021]
[2]杨锦龙,刘 欢,吕秋菊,等.非糖尿病患者糖化血红蛋白和胰岛素抵抗与 冠状动脉病变程度的相关性研究[J].医学信息,2018,31(10):93.[doi:10.3969/j.issn.1006-1959.2018.10.028]
　YANG Jin-long,LIU Huan,LV Qiu-ju,et al.Correlation between Glycosylated Hemoglobin and Insulin Resistance and Severity of Coronary Artery Disease in Non-diabetic Patients[J].Medical Information,2018,31(01):93.[doi:10.3969/j.issn.1006-1959.2018.10.028]
[3]袁 奔,潘 伟,罗淑红,等.体重指数对多囊卵巢综合征患者 人工授精妊娠结局影响[J].医学信息,2018,31(12):99.[doi:10.3969/j.issn.1006-1959.2018.12.030]
　YUAN Ben,PAN Wei,LUO Shu-hong,et al.Effects of Body Mass Index on the Outcome of Artificial Insemination in Patients with Polycystic Ovary Syndrome[J].Medical Information,2018,31(01):99.[doi:10.3969/j.issn.1006-1959.2018.12.030]
[4]李德君,李慧君.来曲唑联合苍附导痰汤治疗多囊卵巢综合征不孕症患者的 临床观察[J].医学信息,2018,31(17):137.[doi:10.3969/j.issn.1006-1959.2018.17.043]
　LI De-jun,LI Hui-jun.Clinical Observation of Letrozole Combined with Cangfu Daotan Decoction in the Treatment of Infertility Patients with Polycystic Ovary Syndrome[J].Medical Information,2018,31(01):137.[doi:10.3969/j.issn.1006-1959.2018.17.043]
[5]曾利文,陈 静,张 晔,等.多囊卵巢综合征患者的糖代谢特点分析[J].医学信息,2019,32(02):103.[doi:10.3969/j.issn.1006-1959.2019.02.029]
　ZENG Li-wen,CHEN Jing,ZHANG Ye,et al.Analysis of Characteristics of Glucose Metabolism in Patients with Polycystic Ovarian Syndrome[J].Medical Information,2019,32(01):103.[doi:10.3969/j.issn.1006-1959.2019.02.029]
[6]谢小莉,李 燕,霍 敏,等.老年2型糖尿病患者轻度认知功能障碍与胰岛素抵抗、 白介素-6的相关性研究[J].医学信息,2019,32(15):97.[doi:10.3969/j.issn.1006-1959.2019.15.030]
　XIE Xiao-li,LI Yan,HUO Min,et al.Correlation between Mild Cognitive Impairment and Insulin Resistance and Interleukin-6 in Elderly Type 2 Diabetic Patients[J].Medical Information,2019,32(01):97.[doi:10.3969/j.issn.1006-1959.2019.15.030]
[7]刘柏基,熊波波.代谢综合征与良性前列腺增生合并下尿路症状的关系 及治疗研究[J].医学信息,2019,32(17):28.[doi:10.3969/j.issn.1006-1959.2019.17.010]
　LIU Bai-ji,XIONG Bo-bo.Relationship between Metabolic Syndrome and Benign Prostatic Hyperplasia with Lower Urinary Tract Symptoms and Treatment[J].Medical Information,2019,32(01):28.[doi:10.3969/j.issn.1006-1959.2019.17.010]
[8]赵 猛,孙 娟,褚 璇.苯扎贝特改善2型糖尿病合并高甘油三酯血症患者 胰岛素抵抗的临床分析[J].医学信息,2019,32(17):145.[doi:10.3969/j.issn.1006-1959.2019.17.048]
　ZHAO Meng,SUN Juan,CHU Xuan.Clinical Analysis of Bezafibrate in Improving Insulin Resistance in Patients with Type 2 Diabetes Mellitus Complicated with Hypertriglyceridemia[J].Medical Information,2019,32(01):145.[doi:10.3969/j.issn.1006-1959.2019.17.048]
[9]李淑娟,王爱芹,杨学军,等.子宫内膜息肉发病相关危险因素临床分析[J].医学信息,2019,32(13):119.[doi:10.3969/j.issn.1006-1959.2019.13.035]
　LI Shu-juan,WANG Ai-qin,YANG Xue-jun,et al.Clinical Analysis of Risk Factors Related to the Incidence of Endometrial Polyps[J].Medical Information,2019,32(01):119.[doi:10.3969/j.issn.1006-1959.2019.13.035]
[10]陈 月,任 伟.胰岛素抵抗与肌少症关系的研究[J].医学信息,2019,32(23):42.[doi:10.3969/j.issn.1006-1959.2019.23.011]
　CHEN Yue,REN Wei.Study on the Relationship Between Insulin Resistance and Sarcopenia[J].Medical Information,2019,32(01):42.[doi:10.3969/j.issn.1006-1959.2019.23.011]
[11]朱 艳,周 琴,安 洁,等.脂联素基因单核苷酸多态性与多囊卵巢综合征伴胰岛素抵抗的关系研究[J].医学信息,2020,33(22):87.[doi:10.3969/j.issn.1006-1959.2020.22.025]
　ZHU Yan,ZHOU Qin,AN Jie,et al.Study on the Relationship Between Adiponectin Gene Single Nucleotide Polymorphism and Polycystic Ovary Syndrome with Insulin Resistance[J].Medical Information,2020,33(01):87.[doi:10.3969/j.issn.1006-1959.2020.22.025]
[12]陈 丽,郝丽娟.多囊卵巢综合征患者腹型肥胖、高雄、胰岛素抵抗及脂代谢的相关性分析[J].医学信息,2022,35(12):113.[doi:10.3969/j.issn.1006-1959.2022.12.027]
　CHEN Li,HAO Li-juan.Correlation of Abdominal Obesity, Hyperandrogenism, Insulin Resistance and Lipid Metabolism in Patients with Polycystic Ovary Syndrome[J].Medical Information,2022,35(01):113.[doi:10.3969/j.issn.1006-1959.2022.12.027]
[13]牛佳莉,陆美茵,刘 斌.实验室检查指标对于多囊卵巢综合征患者排卵障碍的筛查效能[J].医学信息,2023,36(03):93.[doi:10.3969/j.issn.1006-1959.2023.03.019]
　NIU Jia-li,LU Mei-yin,LIU Bin.Efficacy of Laboratory Test Indicators for Screening Ovulation Disorders in Patients with Polycystic Ovary Syndrome[J].Medical Information,2023,36(01):93.[doi:10.3969/j.issn.1006-1959.2023.03.019]

更新日期/Last Update: 1900-01-01